Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 11 2025
0mins
Should l Buy NTRB?
Source: Newsfilter
CEO Transition: Gareth Sheridan, CEO of Nutriband Inc., will temporarily step down to run for the Irish Presidential election, with Chairman Serguei Melnik taking over as interim CEO during this period.
AVERSA Fentanyl Development: Nutriband's AVERSA Fentanyl patch, designed to deter abuse and misuse, has received FDA approval for a meeting request, with potential annual US sales estimated between $80 million to $200 million.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTRB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTRB
Wall Street analysts forecast NTRB stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.060
Low
15.00
Averages
15.00
High
15.00
Current: 4.060
Low
15.00
Averages
15.00
High
15.00
No data
About NTRB
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nutriband Annual Meeting Update: New Directors and Product Developments
- New Director Appointments: At the Annual Shareholders Meeting on January 24, 2026, Nutriband appointed two new directors, Alessandro Puddu and Viorica Carlig, with Puddu bringing over 10 years of experience in audit and financial reporting, while Carlig adds extensive leadership and compliance expertise, enhancing the company's governance and strategic execution capabilities.
- AVERSA™ FENTANYL Progress: Strengthened collaboration with Kindeva for the exclusive product development of AVERSA™ FENTANYL, where both parties share development costs in exchange for milestone payments, which is expected to accelerate product commercialization and enhance market competitiveness.
- Patent Protection Expansion: Nutriband secured a patent for its AVERSA™ abuse deterrent platform technology in Macao, further solidifying its intellectual property and providing legal protection for global market expansion.
- Shareholder Complaint and Penalties: The company filed a complaint with FINRA to investigate suspected naked short selling and has collected $30,000 in penalties to extend the closing date, which will help protect shareholder interests and bolster market confidence.
See More
Nutriband Sells 90% of Subsidiary for $5M, Enhancing Shareholder Value
- Shareholder Value Enhancement: Nutriband's agreement to sell 90% of its Pocono subsidiary for $5M will add $5M to its bottom line without diluting existing shareholders, demonstrating the company's commitment to shareholder value.
- Preferred Stock Dividend: In July 2025, Nutriband issued a 25% preferred stock dividend to existing shareholders, providing one preferred share for every four common shares held, thereby enhancing shareholder returns and loyalty.
- Strengthened Patent Protection: Nutriband received a U.S. patent for its AVERSA™ Fentanyl product in 2025, significantly bolstering its intellectual property portfolio and laying the groundwork for future commercialization, showcasing its technological edge in drug safety.
- Market Expansion: Nutriband's inclusion in four major indexes, including Russell Microcap and Russell 3000E, enhances its market visibility and investment appeal, potentially attracting more investors to its future growth prospects.
See More
Nutriband Sells 90% of Subsidiary for $5M, Enhancing Shareholder Value
- Enhanced Shareholder Value: Nutriband's agreement to sell 90% of its Pocono subsidiary for $5M is expected to add $5M to the bottom line without diluting shareholders, demonstrating the company's commitment to maximizing shareholder value.
- Preferred Stock Dividend: In July 2025, Nutriband issued a 25% preferred stock dividend to existing shareholders, providing one preferred share for every four common shares held, which further enhances returns for investors and strengthens shareholder loyalty.
- Strengthened Patent Protection: Nutriband received a U.S. patent for its AVERSA™ Fentanyl product in 2025, significantly bolstering its intellectual property portfolio and laying a solid foundation for future commercialization, showcasing the company's innovative capabilities in drug safety technology.
- Index Inclusion Expansion: In 2025, Nutriband was added to four major indexes, including the Russell Microcap and Russell 3000E, which enhances the company's market visibility and investor interest, likely attracting more attention from potential investors.
See More
Nutriband Sells 90% of Subsidiary for $5M, No Dilution for Shareholders
- Strategic Transaction: Nutriband has agreed to sell 90% of its Pocono subsidiary for $5 million, which will add $5 million to the company's bottom line while ensuring no dilution for shareholders, reflecting the company's commitment to shareholder value.
- Shareholder Returns: In July 2025, Nutriband issued a 25% preferred stock dividend to all existing shareholders, allowing shareholders of record on July 25 to receive one preferred share for every four common shares held, thereby enhancing shareholder returns.
- Enhanced Patent Protection: In June 2025, Nutriband received patent number 12,318,492 from the USPTO, further strengthening its intellectual property protection for the AVERSA™ technology, laying the groundwork for future commercialization.
- Market Expansion: Nutriband successfully joined four indexes in 2025, including the Russell Microcap and Russell 3000E, which boosts the company's market visibility and investment appeal, indicating enhanced growth potential ahead.
See More
Nutriband Sells 90% Stake in Pocono Pharmaceutical for $5 Million
- Stake Sale Agreement: Nutriband has signed an agreement to sell a 90% stake in its subsidiary Pocono Pharmaceutical for $5 million to EarthVision Bio, with the transaction expected to close on December 31, 2025, marking a significant step in the company's strategic restructuring.
- Shareholder Equity Retention: Following the completion of the sale, Nutriband shareholders will retain a 10% ownership stake in EarthVision Bio, which not only ensures continued participation in the new company but also potentially provides opportunities for future value appreciation.
- Planned Use of Proceeds: Nutriband intends to use the proceeds from this sale to support the ongoing development of AVERSA Fentanyl, an abuse-deterrent transdermal fentanyl patch designed to reduce misuse and accidental exposure, demonstrating the company's commitment to innovative products.
- Positive Market Reaction: Nutriband's shares rose 16% to $5.57 following the announcement of the transaction, reflecting market optimism regarding the company's strategic adjustments and future growth potential.
See More
Nutriband Sells 90% Stake in Pocono Pharmaceutical for $5 Million
- Stake Sale: Nutriband has agreed to sell a 90% stake in its subsidiary Pocono Pharmaceutical for $5 million, which will provide the company with capital to support the development of its core products.
- Continued Investment: Proceeds from the sale will be directed towards the ongoing development of AVERSA Fentanyl, which has the potential to become the world's first abuse-deterrent opioid patch, with projected annual sales ranging from $80 million to $200 million.
- Shareholder Retention: Following the transaction, Nutriband shareholders will retain a 10% stake in EarthVision Bio, ensuring continued shareholder interest and potentially providing an additional revenue stream for future growth.
- Sustainability Focus: EarthVision Bio's development of sustainable products aims to replace plastics and other traditional materials, aligning with the growing market demand for eco-friendly alternatives and enhancing Nutriband's strategic position in the sustainability sector.
See More
Nutriband Annual Meeting Update: New Directors and Product Developments
- New Director Appointments: At the Annual Shareholders Meeting on January 24, 2026, Nutriband appointed two new directors, Alessandro Puddu and Viorica Carlig, with Puddu bringing over 10 years of experience in audit and financial reporting, while Carlig adds extensive leadership and compliance expertise, enhancing the company's governance and strategic execution capabilities.
- AVERSA™ FENTANYL Progress: Strengthened collaboration with Kindeva for the exclusive product development of AVERSA™ FENTANYL, where both parties share development costs in exchange for milestone payments, which is expected to accelerate product commercialization and enhance market competitiveness.
- Patent Protection Expansion: Nutriband secured a patent for its AVERSA™ abuse deterrent platform technology in Macao, further solidifying its intellectual property and providing legal protection for global market expansion.
- Shareholder Complaint and Penalties: The company filed a complaint with FINRA to investigate suspected naked short selling and has collected $30,000 in penalties to extend the closing date, which will help protect shareholder interests and bolster market confidence.
See More
Nutriband Sells 90% of Subsidiary for $5M, Enhancing Shareholder Value
- Shareholder Value Enhancement: Nutriband's agreement to sell 90% of its Pocono subsidiary for $5M will add $5M to its bottom line without diluting existing shareholders, demonstrating the company's commitment to shareholder value.
- Preferred Stock Dividend: In July 2025, Nutriband issued a 25% preferred stock dividend to existing shareholders, providing one preferred share for every four common shares held, thereby enhancing shareholder returns and loyalty.
- Strengthened Patent Protection: Nutriband received a U.S. patent for its AVERSA™ Fentanyl product in 2025, significantly bolstering its intellectual property portfolio and laying the groundwork for future commercialization, showcasing its technological edge in drug safety.
- Market Expansion: Nutriband's inclusion in four major indexes, including Russell Microcap and Russell 3000E, enhances its market visibility and investment appeal, potentially attracting more investors to its future growth prospects.
See More
Nutriband Sells 90% of Subsidiary for $5M, Enhancing Shareholder Value
- Enhanced Shareholder Value: Nutriband's agreement to sell 90% of its Pocono subsidiary for $5M is expected to add $5M to the bottom line without diluting shareholders, demonstrating the company's commitment to maximizing shareholder value.
- Preferred Stock Dividend: In July 2025, Nutriband issued a 25% preferred stock dividend to existing shareholders, providing one preferred share for every four common shares held, which further enhances returns for investors and strengthens shareholder loyalty.
- Strengthened Patent Protection: Nutriband received a U.S. patent for its AVERSA™ Fentanyl product in 2025, significantly bolstering its intellectual property portfolio and laying a solid foundation for future commercialization, showcasing the company's innovative capabilities in drug safety technology.
- Index Inclusion Expansion: In 2025, Nutriband was added to four major indexes, including the Russell Microcap and Russell 3000E, which enhances the company's market visibility and investor interest, likely attracting more attention from potential investors.
See More
Nutriband Sells 90% of Subsidiary for $5M, No Dilution for Shareholders
- Strategic Transaction: Nutriband has agreed to sell 90% of its Pocono subsidiary for $5 million, which will add $5 million to the company's bottom line while ensuring no dilution for shareholders, reflecting the company's commitment to shareholder value.
- Shareholder Returns: In July 2025, Nutriband issued a 25% preferred stock dividend to all existing shareholders, allowing shareholders of record on July 25 to receive one preferred share for every four common shares held, thereby enhancing shareholder returns.
- Enhanced Patent Protection: In June 2025, Nutriband received patent number 12,318,492 from the USPTO, further strengthening its intellectual property protection for the AVERSA™ technology, laying the groundwork for future commercialization.
- Market Expansion: Nutriband successfully joined four indexes in 2025, including the Russell Microcap and Russell 3000E, which boosts the company's market visibility and investment appeal, indicating enhanced growth potential ahead.
See More
Nutriband Sells 90% Stake in Pocono Pharmaceutical for $5 Million
- Stake Sale Agreement: Nutriband has signed an agreement to sell a 90% stake in its subsidiary Pocono Pharmaceutical for $5 million to EarthVision Bio, with the transaction expected to close on December 31, 2025, marking a significant step in the company's strategic restructuring.
- Shareholder Equity Retention: Following the completion of the sale, Nutriband shareholders will retain a 10% ownership stake in EarthVision Bio, which not only ensures continued participation in the new company but also potentially provides opportunities for future value appreciation.
- Planned Use of Proceeds: Nutriband intends to use the proceeds from this sale to support the ongoing development of AVERSA Fentanyl, an abuse-deterrent transdermal fentanyl patch designed to reduce misuse and accidental exposure, demonstrating the company's commitment to innovative products.
- Positive Market Reaction: Nutriband's shares rose 16% to $5.57 following the announcement of the transaction, reflecting market optimism regarding the company's strategic adjustments and future growth potential.
See More
Nutriband Sells 90% Stake in Pocono Pharmaceutical for $5 Million
- Stake Sale: Nutriband has agreed to sell a 90% stake in its subsidiary Pocono Pharmaceutical for $5 million, which will provide the company with capital to support the development of its core products.
- Continued Investment: Proceeds from the sale will be directed towards the ongoing development of AVERSA Fentanyl, which has the potential to become the world's first abuse-deterrent opioid patch, with projected annual sales ranging from $80 million to $200 million.
- Shareholder Retention: Following the transaction, Nutriband shareholders will retain a 10% stake in EarthVision Bio, ensuring continued shareholder interest and potentially providing an additional revenue stream for future growth.
- Sustainability Focus: EarthVision Bio's development of sustainable products aims to replace plastics and other traditional materials, aligning with the growing market demand for eco-friendly alternatives and enhancing Nutriband's strategic position in the sustainability sector.
See More
